about us

The Variant Bio Team

Our team has a passion for exploration, and expertise spanning genetics, molecular biology, therapeutics, anthropology, and ethics. We started Variant Bio because we share the belief that human genomics has the power to transform drug development.

Katie Anderson
Isabella Apriyana
Heather Arnett
Molly Blank
Katie Anderson

Target Biology

Isabella Apriyana

Fellow

Heather Arnett, PhD

VP, Research

Molly Blank, PhD

Digital and Diagnostic Solutions

Erin Burke
Stephane Castel
Noah Collins
Anne-Katrin Emde
Erin Burke, PhD

Biological Anthroplogy

Stephane Castel, PhD

Chief Technology Officer

Noah Collins

Medical Anthropology

Anne-Katrin Emde, PhD

Bioinformatics

Andrew Farnum
Rob Flickenger
C. Scott Gallagher
Paloma Guzzardo
Andrew Farnum

Chief Executive Officer

Rob Flickenger

Research Infrastructure

C. Scott Gallagher, PhD

Statistical Genetics

Paloma Guzzardo, PhD

Target Biology

Iman Hamid
Melissa Hendershott
Leslie Hepner
Alon Keinan
Iman Hamid

Population Genetics

Melissa Hendershott, PhD

Partnership Operations

Leslie Hepner

Operations

Alon Keinan, PhD

Sr. Director, Population Genetics

Sarah LeBaron von Baeyer
Tony Lee
Khanh-Dung Nguyen
Rindra Rakotoarivony
Sarah LeBaron von Baeyer, PhD

Cultural Anthropology

Tony Lee

Software Engineering

Khanh-Dung Nguyen, PhD

Functional Genomics

Rindra Rakotoarivony, PhD

Fellow

Tom Rush
Samia Shamim
Mario Trejo
Kaja Wasik
Tom Rush, PhD

Chief R&D Officer

Samia Shamim

Business Development

Mario Trejo, PhD

Medical Epidemiology

Kaja Wasik, PhD

Chief Science Officer

Laura Yerges-Armstrong
Laura Yerges-Armstrong, PhD

VP, Computational Genetics

Our Board

Josh Wolfe
Elena Viboch
Bob More
Stuart Nagae
Josh Wolfe

Co-founder and Managing Partner, Lux Capital

Elena Viboch

Investment Director, SoftBank Vision Fund

Bob More

Managing Director, Alta Partners

Stuart Nagae

Director, Vulcan Capital

Julie Sunderland
Julie Sunderland

Co-founder and Managing Director, Biomatics Capital

Our Scientific Advisory Board

Karen Akinsanya
Rob Hershberg
David McElligott
Rob Scott
Karen Akinsanya, PhD

Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D, Schrödinger

Rob Hershberg, MD, PhD

Venture Partner, Frazier and Former CSO, Celgene

David McElligott, PhD

CSO, Petra Pharma

Rob Scott, MD

Former CMO, Abbvie

Our Senior Advisors

Jay Flatley
Keolu Fox
Tuuli Lappalainen
Daniel MacArthur
Jay Flatley

Former CEO/Executive Chairman, Illumina

Keolu Fox, PhD

Assistant Professor, University of California, San Diego

Tuuli Lappalainen, PhD

Associate Professor, Columbia University

Daniel MacArthur, PhD

Director, Centre for Population Genomics, Garvan Institute of Medical Research and Murdoch Children's Research Institute

Kiran Musunuru
Fernando Racimo
Michael Schatz
Bruce Stillman
Kiran Musunuru, MD, PhD

Associate Professor, University of Pennsylvania

Fernando Racimo, PhD

Assistant Professor, University of Copenhagen

Michael Schatz, PhD

Associate Professor, Johns Hopkins University

Bruce Stillman, PhD

President, Cold Spring Harbor Laboratory

Our Ethics Advisory Board

Misha Angrist
Adia Benton
Laura Hercher
Huti Watson
Misha Angrist, PhD

Misha is an Associate Professor of the Practice in the Social Science Research Institute at Duke University. His research and teaching focus on science writing and the governance of human participation in research and medicine.

Adia Benton, PhD

Adia is an Associate Professor of Cultural Anthropology at Northwestern University. She specializes in global health, biomedicine, and development and humanitarianism, and in sub-Saharan Africa and Southeast Asia in particular.

Laura Hercher, MS

Laura is the Director of Research for the Graduate Program in Human Genetics at Sarah Lawrence College. She has expertise in genetic counseling and the ethical, legal, and social dimensions of genetic medicine.

Huti Watson

Huti is Chair of Genomics Aotearoa’s Variome Project governance group and Deputy Chair of Ngāti Porou Hauora, a tribal health provider in New Zealand. She is an expert on the interface between Māori knowledge and science.

Our Investors

Lux Capital
SoftBank
Alta Partners
General Catalyst
Casdin Capital
Vulcan Capital
Sahsen Ventures
Alexandria Venture Investments